AzTrials
AzTrials

Intracranial MeningiomaNCT05832099

Cognition-preserving Brain Irradiation for Treating Patients With Intracranial Meningioma in the Era of Modern Radiotherapeutic Techniques Including Proton Beam Therapy - a Prospective Study Focusing on Radiological Outcomes and Neurocognitive Endpoints

An observational study of Intracranial Meningioma, run by Chang Gung Memorial Hospital at 1 site in Taiwan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

【Background】For cranial-irradiation-naive patients with intracranial meningiomas at risk of local recurrence, the administration of conformal cranial radiotherapy can enhance tumor control in the current era of modern radiotherapeutic techniques. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Intracranial Meningioma
What is being tested?
Radiation
Type of treatment
Surgery or procedure
How many people
74 participants
Where
1 siteTaiwan
Study dates
1 Aug 2023to 31 Jul 2026
How long will I take part?
24 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with clinically or pathologically-confirmed intracranial non-malignant meningiomas referred for arranging conformal focal-brain irradiation using modern radiotherapeutic techniques including volumetric modulated arc therapy (VMAT), hypofractionated stereotactic radiotherapy (SRT), and proton beam therapy.

Who may be able to join

  • Patients with clinically or pathologically-confirmed intracranial non-malignant meningiomas who are at least 18 years old, referred for arranging conformal radiotherapy
  • A Fair/good performance status superior to Eastern Cooperative Group (ECOG) of 2 or an acceptable performance status of Karnofsky Score (KPS) at least 70

Who cannot join

  • History of prior radiotherapy delivered to brain/head region for any reason, including stereotactic radiosurgery
  • Patients with malignant meningiomas diagnosed pathologically (WHO grade III)
  • Patients with presumed clinical target volume (CTV) encompassing bilateral peri-hippocampal regions within 5 mm away from the adjacent periphery of the hippocampus
  • Patients whose quality of volumetric MRI fails to meet the minimal requirements for physicians to delineate the hippocampal contouring (i.e., slice thickness > 2mm)

Trial locations and contacts

1 site in 1 country.

Chi-Cheng Chuang, M.D. contact

+88633281200 ext. 2412

ccc2915@cgmh.org.tw

Taiwan1 site
  • Chang Gung Memorial Hospital

    Taoyuan, 333

Other trials in Taiwan

About this study

【Background】For cranial-irradiation-naive patients with intracranial meningiomas at risk of local recurrence, the administration of conformal cranial radiotherapy can enhance tumor control in the current era of modern radiotherapeutic techniques. Life expectancy in patients with intracranial meningiomas, particularly non-malignant meningiomas (WHO grade I and II) is essentially similar to people of general population. However, RT-related neurocognitive function (NCF) sequelae are potentially and seriously a concern which should not be ignored. In terms of the natural course of cranial irradiation-induced NCF decline, it might vary considerably according to the specific domains which are selected to be measured. Early neurocognitive decline principally involves impairments of episodic memory, which is significantly associated with functions of the hippocampus. Additionally, the extent of changes in hippocampal volume after local irradiation may be associated with the hippocampal dosimetry. This study thus aims to investigate the potential cause-effect relationship between the hippocampal dosimetry and radiological outcomes represented by the volumetric changes regarding the contralateral hippocampus; furthermore, the correlation between radiological outcomes and neurocognitive endpoints will be examined and clarified.

【Methods】Patients with cranial-RT-naive intracranial meningiomas may be eligible and therefore enrolled in this prospective study addressing both radiological outcomes and neurocognitive endpoints. All eligible and recruited patients should receive baseline volumetric brain MRI examination and baseline neurobehavioral assessment. Subsequently, conformal cranial irradiation in the era of modern radiotherapeutic techniques (including hypofractionated stereotactic radiotherapy, proton beam therapy volumetric modulated arc therapy) will be utilized in order to reduce the dose irradiating the contralateral hippocampus and other relevant organs at risk. The prescribed dose schemes for treating patients with intracranial meningioma depend on the decision of the radiation oncologist in charge and follow the treatment guidelines at our cancer center. Accordingly, a battery of neurocognitive measures, which includes 9 standardized neuropsychological tests categorized into 5 NCF domains (e.g., executive functions, verbal \& non-verbal memory, working memory, psychomotor speed, and amygdala-related emotion recognition), is used to evaluate neurocognitive performances longitudinally for our registered patients. There will be two co-primary outcome measures in the current study. The main primary outcome will be the correlation between the mean hippocampal dose and the extent of change in hippocampal volume at 6 months after the course of cranial RT. The other primary endpoint will be 6-month cognitive-deterioration-free survival.

【Expected Results】This prospective observational cohort study aims to explore and investigate the cause-effect relationship between the hippocampal dosimetry (i.e., mean dose irradiating the hippocampus, particularly the one contralateral to the lateralization of intracranial meningioma) and the extent of hippocampal atrophy signifying one of the measures regarding radiological outcomes. Simultaneously, predefined standardized neurocognitive outcome measures such as hippocampus-related memory functions and amygdala-related emotion recognition will be obtained prospectively and longitudinally in order to examine whether any meaningfully significant correlation exists between the above radiological outcome measures and neurocognitive endpoints. The mutual associations among hippocampal dosimetry, radiological outcomes including the MRI-delineated hippocampal volume, and neurocognitive endpoints including hippocampus-related verbal/non-verbal memory functions will be examined thoroughly.

Being tested
Radiation
Keywords
Intracranial Meningioma, Radiation Therapy, Magnetic Resonance Image (MRI), Volumetric MRI, Functional MRI (fMRI), Radiological Outcomes, Hippocampus, Neurocognitive Functions (NCFs), Cognition-Preserving Brain Radiotherapy, Proton Beam Radiotherapy, Hippocampal Atrophy, Amygdala, Thalamus
Medical subject headings
Meningioma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RadiationRadiation

    The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)

Study groups in NCT05832099
Study groupRoleWhat they receive
RadiationConformal focal-brain irradiation using modern radiotherapeutic techniques (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
Receives: Radiation: Radiation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Longitudinal changes in the volumes of organs at risk including the hippocampus

    Longitudinal changes in the volumes (cc) of the left hippocampus, right hippocampus, left amygdala, right amygdala, left thalamus, right thalamus, and so on based on volumetric MR imaging examinations

    Measured: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months

Secondary outcomes (8)
  1. Change in verbal memory function

    Change in verbal memory function related to left hippocampus from baseline to 4 months after cognition-preserving cranial RT

    Measured: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months

  2. Change in non-verbal memory learning

    Change in non-verbal memory learning associated with right hippocampus from baseline to 4 months after cognition-preserving brain RT

    Measured: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months

  3. Change in executive function

    Change in executive function related to hippocampus from baseline to 4 months after cognition-preserving cranial RT.

    Concerning the domain of executive functions generally dominated by the frontal lobes, the Modified Card Sorting Test is employed to assess both conceptual formation and mental shifting which have been documented to be the major components of executive functions.

    Measured: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months

  4. Change in emotion memory task

    Change in emotion memory tasks associated with the amygdala from baseline to 4 months after cognition-reserving cranial irradiation.

    For evaluate and quantify the cognitive function of amygdala, the NCF test tailored to the emotional recognition task will be used and patients' performances will be assessed using the commercialized and computerized test included in Cambridge Cognition® package.

    Measured: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months

  5. Change in working memory

    Change in working memory related to hippocampus from baseline to 4 months after cognition-preserving cranial RT.

    Working memory includes executive functions and psychomotor speed.

    • The neurocognitive outcome of verbal working memory was determined by the Digit Span Subtest (DS) and Spatial Span (SSP) of the Wechsler Adult Intelligence Scale- 3rd edition (WAIS-III®).
    • In order to indicate patients' performance on the psychomotor speed, we make use of Psychomotor Speed Index (PSI), which is derived from the composite score of Digit Symbol Coding Subtest (DSS) and Symbol Searching Subtest (SS) of the WAIS-III®.

    Measured: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months

  6. Longitudinal changes in the imaging biomarkers

    Longitudinal changes in the imaging biomarkers from DTI imaging

    Measured: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months

  7. Longitudinal changes in the fractional anisotropy

    Longitudinal changes in the fractional anisotropy (FA, unitless index between 0 and 1) from DTI imaging

    Measured: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months

  8. Trajectories in the imaging biomarker

    Trajectories in the imaging biomarker, mean diffusivity (MD, mm squared/second) based on DTI imaging

    Measured: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Apr 2023
  2. Study start1 Aug 2023 (estimated)
  3. Primary completion31 Jul 2026 (estimated)
  4. Study completion31 Jul 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
74 participants (estimated)
Target duration
24 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT05832099
Sponsor's protocol ID
202202092A3
Status last verified
Dec 2022
First submitted
15 Mar 2023
Last updated
27 Apr 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Intracranial Meningioma, run by Chang Gung Memorial Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 27 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Chi-Cheng Chuang, M.D. (+88633281200 ext. 2412, ccc2915@cgmh.org.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Longitudinal changes in the volumes of organs at risk including the hippocampus (time frame: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in